Immuneering Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Benjamin J. Zeskind
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 245 Main Street Cambridge MA United States of America 02142
- IPO Date
- Jul 30, 2021
- CIK
- 0001790340
- Website
- immuneering.com
- Similar Companies
- Business
- Immuneering Corporation (IMRX) Immuneering Corporation, a clinical-stage oncology company, develops novel small molecule therapeutics targeting the RAS/RAF/MEK signaling pathway for patients with advanced solid tumors; its lead product candidate atebimetinib (IMM-1-104), an oral once-daily deep cyclic MEK inhibitor, advances through Phase 2a trials in pancreatic cancer, melanoma, and non-small cell lung cancer (NSCLC), including monotherapy and planned combinations with chemotherapy, PD-1 inhibitors, BRAF inhibitors, and KRAS G12C inhibitors under clinical supply agreements with Eli Lilly and Regeneron; IMM-6-415, an oral twice-daily deep cyclic MEK inhibitor, progresses in Phase 1/2a trials for RAS- or RAF-mutant solid tumors; the company leverages its proprietary Disease Canceling Technology platform, integrating bioinformatics, machine learning, and human data, to design selective inhibitors that modulate signaling dynamics for improved tolerability across broad patient populations. Immuneering Corporation operates primarily in the United States from its headquarters at 245 Main Street, Second Floor, Cambridge, Massachusetts; founded in 2008 by computational biology experts including CEO Benjamin Zeskind alongside MIT researchers Forest White and Doug Lauffenburger, the firm shifted from bioinformatics services around 2015 to internal drug development following Series A funding in 2019 and its 2021 Nasdaq IPO that raised approximately $129 million. In September 2025, Immuneering Corporation completed a $175 million public offering of 18.96 million Class A shares at $9.23 per share, concurrent with a $25 million private placement to Sanofi purchasing 2.71 million shares at the same price, generating approximately $200 million in gross proceeds to fund preclinical and clinical programs through at least 2029 including a planned pivotal Phase 3 trial for atebimetinib; these transactions, underwritten by Leerink Partners and Oppenheimer & Co. with a 30-day overallotment option, followed a shelf registration effective in August 2025 and an August funding round of nearly $25 million from nine investors.
Company News
Immuneering to Participate in Upcoming Investor Conferences
Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
Immuneering Corporation Announces Grants of Inducement Awards
Immuneering Corporation Announces Grants of Inducement Awards
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering Appoints Andrew Gengos as Chief Financial Officer
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Corporation: Updates Inbound At The End Of The Month
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond